These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30220530)

  • 41. Comparative Proteomic Analysis of Rapamycin Versus Cyclosporine Combination Treatment in Mouse Podocytes.
    Kim BS; Cho Y; Lee H; Joo DJ; Huh KH; Kim MS; Kim YS
    Transplant Proc; 2016 May; 48(4):1297-301. PubMed ID: 27320608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ATF3 activates Stat3 phosphorylation through inhibition of p53 expression in skin cancer cells.
    Hao ZF; Ao JH; Zhang J; Su YM; Yang RY
    Asian Pac J Cancer Prev; 2013; 14(12):7439-44. PubMed ID: 24460316
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients.
    Smith KJ; Hamza S; Skelton H
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):634-41. PubMed ID: 15061848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling.
    Sully K; Akinduro O; Philpott MP; Naeem AS; Harwood CA; Reeve VE; O'Shaughnessy RF; Byrne C
    Oncogene; 2013 Jul; 32(27):3254-62. PubMed ID: 22890326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic UV radiation-induced RORγt+ IL-22-producing lymphoid cells are associated with mutant KC clonal expansion.
    Lewis JM; Monico PF; Mirza FN; Xu S; Yumeen S; Turban JL; Galan A; Girardi M
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34504008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MHY1485 ameliorates UV-induced skin cell damages via activating mTOR-Nrf2 signaling.
    Yang B; Xu QY; Guo CY; Huang JW; Wang SM; Li YM; Tu Y; He L; Bi ZG; Ji C; Cheng B
    Oncotarget; 2017 Feb; 8(8):12775-12783. PubMed ID: 28061443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of cyclosporine, tacrolimus and sirolimus on cellular senescence in renal epithelial cells.
    Koppelstaetter C; Kern G; Leierer G; Mair SM; Mayer G; Leierer J
    Toxicol In Vitro; 2018 Apr; 48():86-92. PubMed ID: 29309803
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rapamycin Inhibitors for Eye Squamous Cell Carcinoma after Renal Transplantation: A Case Report.
    Infante B; Coviello N; Troise D; Gravina M; Bux V; Castellano G; Stallone G
    Kidney Blood Press Res; 2021; 46(1):121-125. PubMed ID: 33508825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
    Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
    Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
    Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
    Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blocking the ATR-SerRS-VEGFA pathway targets angiogenesis for UV-induced cutaneous squamous cell carcinoma.
    Lu H; Peng Z; Zheng Z; Li C; Wang Y; Liang L; Chen Y; Zeng K
    Mol Carcinog; 2024 Jun; 63(6):1160-1173. PubMed ID: 38695641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The ARE-binding protein Tristetraprolin (TTP) is a novel target and mediator of calcineurin tumor suppressing function in the skin.
    Wu X; Tommasi di Vignano A; Zhou Q; Michel-Dziunycz PJ; Bai F; Mi J; Qin J; Zu T; Hofbauer GFL
    PLoS Genet; 2018 May; 14(5):e1007366. PubMed ID: 29723192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cutaneous squamous cell carcinoma (cSCC) and immunosurveillance - the impact of immunosuppression on frequency of cSCC.
    Plasmeijer EI; Sachse MM; Gebhardt C; Geusau A; Bouwes Bavinck JN
    J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():33-37. PubMed ID: 31833604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.
    Basu A; Liu T; Banerjee P; Flynn E; Zurakowski D; Datta D; Viklicky O; Gasser M; Waaga-Gasser AM; Yang J; Pal S
    Cancer Lett; 2012 Aug; 321(2):179-86. PubMed ID: 22343319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sirolimus, the first mTOR inhibitor.
    Sánchez-Plumed JA; González Molina M; Alonso A; Arias M
    Nefrologia; 2006; 26 Suppl 2():21-32. PubMed ID: 17937632
    [No Abstract]   [Full Text] [Related]  

  • 58. Niacin protects against UVB radiation-induced apoptosis in cultured human skin keratinocytes.
    Lin F; Xu W; Guan C; Zhou M; Hong W; Fu L; Liu D; Xu A
    Int J Mol Med; 2012 Apr; 29(4):593-600. PubMed ID: 22246168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma.
    Farshchian M; Nissinen L; Siljamäki E; Riihilä P; Piipponen M; Kivisaari A; Kallajoki M; Grénman R; Peltonen J; Peltonen S; Quint KD; Bavinck JNB; Kähäri VM
    Oncotarget; 2017 Jul; 8(28):45825-45836. PubMed ID: 28526809
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
    Patsenker E; Schneider V; Ledermann M; Saegesser H; Dorn C; Hellerbrand C; Stickel F
    J Hepatol; 2011 Aug; 55(2):388-98. PubMed ID: 21168455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.